Autopsy report · NCT02603068
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Cause of deathOther
“Study design was inadequate and would not achieve study endpoints”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- United Therapeutics
- Sponsor type
- Industry
- Conditions
- Pulmonary Hypertension; Pulmonary Fibrosis
- Interventions
- Oral treprostinil
- Participants
- 0
- Sites
- 7
- Countries
- United States
Trials that died the same way
- Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
“Study terminated due to lack of feasibility of study design.” - Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
“The study did not meet endpoint.” - A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
“The study did not meet the primary endpoint.” - Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction
“The study was terminated early due to poor participant accrual, resulting in inadequate enrollment to support the planned analysis and study endpoints.” - A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
“Study design was changed”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.